{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T07:42:13Z","timestamp":1768722133281,"version":"3.49.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computers in Biology and Medicine"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.compbiomed.2024.109488","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T20:31:56Z","timestamp":1733171516000},"page":"109488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Unraveling the complexities of immunotherapy for thymic epithelial tumors via bioinformatics and experimental analyses"],"prefix":"10.1016","volume":"185","author":[{"given":"Gaowen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaotong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xitong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.compbiomed.2024.109488_bib1","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.compbiomed.2024.109488_bib2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jtho.2021.10.010","article-title":"The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors?","volume":"17","author":"Marx","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.compbiomed.2024.109488_bib3","doi-asserted-by":"crossref","first-page":"562","DOI":"10.6004\/jnccn.2013.0072","article-title":"Thymomas and thymic carcinomas: clinical practice guidelines in oncology","volume":"11","author":"Ettinger","year":"2013","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.compbiomed.2024.109488_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.lungcan.2016.06.020","article-title":"Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): a single-institution experience","volume":"99","author":"Bluthgen","year":"2016","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.compbiomed.2024.109488_bib5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial [published correction appears in Lancet Oncol. 2015 Mar;16(3):e105]","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol."},{"issue":"23","key":"10.1016\/j.compbiomed.2024.109488_bib6","doi-asserted-by":"crossref","first-page":"9056","DOI":"10.3390\/ijms21239056","article-title":"Immunobiology of thymic epithelial tumors: implications for immunotherapy with immune checkpoint inhibitors","volume":"21","author":"Tateo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.compbiomed.2024.109488_bib7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.lungcan.2020.09.006","article-title":"Everolimus in the treatment of metastatic thymic epithelial tumors","volume":"149","author":"Hellyer","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.compbiomed.2024.109488_bib8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"issue":"3","key":"10.1016\/j.compbiomed.2024.109488_bib9","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","article-title":"Diffuse high intensity PD-L1 staining in thymic epithelial tumors","volume":"10","author":"Padda","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.compbiomed.2024.109488_bib10","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.3390\/jcm8111833","article-title":"PD-L1 expression and tumor-infiltrating lymphocytes in thymic epithelial neoplasms","volume":"8","author":"Higuchi","year":"2019","journal-title":"J. Clin. Med."},{"issue":"24","key":"10.1016\/j.compbiomed.2024.109488_bib11","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.compbiomed.2024.109488_bib12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2019.03.012","article-title":"Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study","volume":"113","author":"Katsuya","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.compbiomed.2024.109488_bib13","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s40425-019-0723-9","article-title":"Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma","volume":"7","author":"Rajan","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.compbiomed.2024.109488_bib14","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1177\/1078155220968150","article-title":"Nivolumab treatment for metastatic thymic epithelial tumors","volume":"27","author":"Ak","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"1","key":"10.1016\/j.compbiomed.2024.109488_bib15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12943-023-01772-4","article-title":"Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives","volume":"22","author":"Ao","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.compbiomed.2024.109488_bib16","article-title":"Immunotherapy: reshape the tumor immune microenvironment","volume":"13","author":"Lv","year":"2022","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.compbiomed.2024.109488_bib17","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","article-title":"Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy","volume":"27","author":"Pitt","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.compbiomed.2024.109488_bib18","article-title":"Prognostic model of eleven genes based on the immune microenvironment in patients with thymoma","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Genet."},{"issue":"11","key":"10.1016\/j.compbiomed.2024.109488_bib19","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.18632\/aging.204108","article-title":"A novel immune-related microRNA signature for prognosis of thymoma","volume":"14","author":"Wang","year":"2022","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.compbiomed.2024.109488_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.895587","article-title":"Identification of immune-related hub genes in thymoma: defects in CD247 and characteristics of paraneoplastic syndrome","volume":"13","author":"Deng","year":"2022","journal-title":"Front. Genet."},{"issue":"13","key":"10.1016\/j.compbiomed.2024.109488_bib21","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1111\/1759-7714.14002","article-title":"Significance of tumor mutation burden and immune infiltration in thymic epithelial tumors","volume":"12","author":"Wang","year":"2021","journal-title":"Thorac. Cancer"},{"issue":"12","key":"10.1016\/j.compbiomed.2024.109488_bib22","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"issue":"1","key":"10.1016\/j.compbiomed.2024.109488_bib23","first-page":"139","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinf."},{"issue":"5","key":"10.1016\/j.compbiomed.2024.109488_bib24","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"issue":"43","key":"10.1016\/j.compbiomed.2024.109488_bib25","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"5","key":"10.1016\/j.compbiomed.2024.109488_bib26","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.compbiomed.2024.109488_bib27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.compbiomed.2024.109488_bib28","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.compbiomed.2024.109488_bib29","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"issue":"Database issue","key":"10.1016\/j.compbiomed.2024.109488_bib30","doi-asserted-by":"crossref","first-page":"D447","DOI":"10.1093\/nar\/gku1003","article-title":"STRING v10: protein-protein interaction networks, integrated over the tree of life","volume":"43","author":"Szklarczyk","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.1016\/j.compbiomed.2024.109488_bib31","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res."},{"issue":"Suppl 4","key":"10.1016\/j.compbiomed.2024.109488_bib32","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1186\/1752-0509-8-S4-S11","article-title":"cytoHubba: identifying hub objects and sub-networks from complex interactome","volume":"8","author":"Chin","year":"2014","journal-title":"BMC Syst. Biol."},{"issue":"8","key":"10.1016\/j.compbiomed.2024.109488_bib33","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.compbiomed.2024.109488_bib34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma [published correction appears in cell. 2017 Jan 26;168(3):542]","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.compbiomed.2024.109488_bib35","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/JTO.0000000000000654","article-title":"The 2015 world health organization classification of tumors of the thymus: continuity and changes","volume":"10","author":"Marx","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.compbiomed.2024.109488_bib36","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1038\/s41598-020-61053-8","article-title":"Immunotherapeutic potential of CD4 and CD8 single-positive T cells in thymic epithelial tumors","volume":"10","author":"Yamamoto","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.compbiomed.2024.109488_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19490976.2021.1886844","article-title":"Modulation of the PI3K\/Akt\/mTOR signaling pathway by probiotics as a fruitful target for orchestrating the immune response","volume":"13","author":"Mohseni","year":"2021","journal-title":"Gut Microb."},{"issue":"2","key":"10.1016\/j.compbiomed.2024.109488_bib38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","article-title":"Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer","volume":"76","author":"Lastwika","year":"2016","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.compbiomed.2024.109488_bib39","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.3390\/cancers13164040","article-title":"PI3K\/Akt pathway: the indestructible role of a vintage target as a support to the most recent immunotherapeutic approaches","volume":"13","author":"Caforio","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.compbiomed.2024.109488_bib40","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/JLB.5RI0220-603RR","article-title":"Harnessing neoantigen specific CD4 T cells for cancer immunotherapy","volume":"107","author":"Brightman","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.compbiomed.2024.109488_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.915837","article-title":"Gamma Delta T-cell based cancer immunotherapy: past-present-future","volume":"13","author":"Saura-Esteller","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.compbiomed.2024.109488_bib42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbadis.2010.12.014","article-title":"Mast cells and inflammation","volume":"1822","author":"Theoharides","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.compbiomed.2024.109488_bib43","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.it.2020.11.001","article-title":"Tolerogenic dendritic cells in autoimmunity and inflammatory diseases","volume":"42","author":"Morante-Palacios","year":"2021","journal-title":"Trends Immunol."},{"issue":"3","key":"10.1016\/j.compbiomed.2024.109488_bib44","first-page":"493","article-title":"Comparative genomics on FGF8, FGF17, and FGF18 orthologs","volume":"16","author":"Katoh","year":"2005","journal-title":"Int. J. Mol. Med."},{"issue":"5","key":"10.1016\/j.compbiomed.2024.109488_bib45","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/path.1668","article-title":"Fibroblast growth factor 17 is over-expressed in human prostate cancer","volume":"204","author":"Heer","year":"2004","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.compbiomed.2024.109488_bib46","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000505695","article-title":"Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits antitumor immunity and enhances programmed cell death-1 checkpoint blockade in hepatocellular carcinoma","volume":"9","author":"Deng","year":"2020","journal-title":"Liver Cancer"},{"issue":"1","key":"10.1016\/j.compbiomed.2024.109488_bib47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","article-title":"FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis","volume":"38","author":"Katoh","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.compbiomed.2024.109488_bib48","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1146\/annurev-immunol-101220-015603","article-title":"B cell function in the tumor microenvironment","volume":"40","author":"Downs-Canner","year":"2022","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.compbiomed.2024.109488_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102376","article-title":"Treg cells in health and autoimmune diseases: new insights from single cell analysis","volume":"110","author":"Scheinecker","year":"2020","journal-title":"J. Autoimmun."},{"issue":"4","key":"10.1016\/j.compbiomed.2024.109488_bib50","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ccell.2020.08.005","article-title":"Conserved interferon-\u03b3 signaling drives clinical response to immune checkpoint blockade therapy in melanoma [published correction appears in cancer cell. 2021 Jan 11;39(1):122]","volume":"38","author":"Grasso","year":"2020","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.compbiomed.2024.109488_bib51","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.compbiomed.2024.109488_bib52","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/s41590-019-0514-y","article-title":"IL-17 receptor-based signaling and implications for disease","volume":"20","author":"Li","year":"2019","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.compbiomed.2024.109488_bib53","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.7150\/thno.15625","article-title":"Role of the CXCL8-CXCR1\/2 Axis in cancer and inflammatory diseases","volume":"7","author":"Ha","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.compbiomed.2024.109488_bib54","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3389\/fimmu.2020.00976","article-title":"CXCR3 ligands in cancer and autoimmunity, chemoattraction of effector T cells, and beyond","volume":"11","author":"Karin","year":"2020","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.compbiomed.2024.109488_bib55","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.compbiomed.2024.109488_bib56","first-page":"691","article-title":"ACKR2: an atypical chemokine receptor regulating lymphatic biology [published correction appears in front immunol. 2017 may 11;8:520]","volume":"7","author":"Bonavita","year":"2017","journal-title":"Front. Immunol."}],"container-title":["Computers in Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482524015737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482524015737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T21:04:00Z","timestamp":1762117440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010482524015737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":56,"alternative-id":["S0010482524015737"],"URL":"https:\/\/doi.org\/10.1016\/j.compbiomed.2024.109488","relation":{},"ISSN":["0010-4825"],"issn-type":[{"value":"0010-4825","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unraveling the complexities of immunotherapy for thymic epithelial tumors via bioinformatics and experimental analyses","name":"articletitle","label":"Article Title"},{"value":"Computers in Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.compbiomed.2024.109488","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109488"}}